Advertisement
Readmissions after thyroid surgery are relatively low

Fewer Than 5 Percent of Thyroid Surgery Patients Readmitted

0
Majority of readmissions occur within seven days of discharge and one-fourth within two days
The costs of oral and injectable brand-name drugs increased from 2008 to 2016

Increase in Brand-Name Drug Cost Mainly Due to Existing Drugs

0
Rising costs of oral, injectable generic and specialty drugs mostly driven by new product entry
Many U.S. female health care workers

Many Female Health Care Workers Live in Poverty

0
Half of black and Latina female health care workers earn less than $15/hour
Eliminating the Affordable Care Act's individual mandate penalty is unlikely to destabilize the individual market in California but could roll back coverage gains

ACA Coverage Gains Could Erode Without Individual Mandate

0
However, individual market in California not expected to destabilize because of mandate penalty
From 1997 through 2016

Medical Marketing Has Increased in Past 20 Years

0
Considerable increase seen from 1997 through 2016, especially in direct-to-consumer advertising
The costs of having two noncommunicable diseases is generally superadditive

Costs Higher for Those With Comorbid Noncommunicable Diseases

0
Health expenditure greater for person with two diseases simultaneously than for the diseases separately
Survivors of childhood Hodgkin lymphoma remain at increased risk for developing subsequent malignant neoplasms

Childhood Hodgkin Lymphoma Survivors at Risk for Later Cancers

0
Survivors have 14-fold increased risk for developing a solid subsequent malignant neoplasm
There is no compelling evidence to indicate health benefits of nonsugar sweetener use on a range of health outcomes

Health Benefits of Nonsugar Sweeteners Uncertain

0
However, large systematic review could not rule out harms from nonsugar sweeteners

December 2018 Briefing – Diabetes & Endocrinology

0
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for December 2018. This roundup includes...
Canagliflozin is not associated with an increased fracture risk versus glucagon-like peptide-1 agonists for middle-aged patients with type 2 diabetes

No Increased Fracture Risk With Canagliflozin in Type 2 Diabetes

0
Rate of the primary outcome was similar for canagliflozin, glucagon-like peptide-1 agonist